Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAH4 is a synthetic, amphipathic, alpha-helical peptide designed for potent antimicrobial activity and efficient nucleic acid transfection. Composed of 26 amino acids with the sequence KKALLALALHHLAHLALHLALALKKA-NH2, it features a leucine-rich hydrophobic face and a histidine-rich hydrophilic face. Its mechanism of action involves pH-dependent membrane interaction; at acidic pH, the protonation of histidine residues promotes membrane insertion and disruption, facilitating the endosomal escape of DNA or RNA cargoes. Primarily used as a research tool, LAH4 demonstrates high affinity for anionic lipids found in bacterial membranes and is frequently employed in laboratory settings to study cell penetration and non-viral gene delivery systems.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LAH4.